Abstract 196P
Background
We sought to explore whether the circulating proliferative T lymphocyte subtypes in patients with advanced gastric cancer (AGC) can be used as an indicator of prognosis.
Methods
Blood samples were collected from patients with AGC before treatment and analyzed by fluorescence-activated cell sorting analysis. Patients were divided into two groups based on the ratio of CD8+ T cells to CD4+ T cells and the ratio of CD8+ T cells to CD4+ T cells within Ki-67+ T cells. Survival between the groups was compared using the Kaplan-Meier method and the log-rank test. Multivariate analyses were also performed.
Results
A total of 92 patients enrolled in the study. The median age was 64.2 years, and the male-to-female ratio was 2.3:1. The median survival duration was 12.5 months. No significant differences in progression-free survival (PFS) and overall survival (OS) were observed between the groups with high and low CD8/CD4 ratios. However, the group with a high ratio of CD8/CD4 within proliferating T cells (n = 46) had a significantly longer OS (16.8 months vs. 11.3 months; p = 0.011) compared to the group with a low ratio of CD8/CD4 within proliferating T cells (n = 46). PFS did not vary between these proliferating CD8/CD4 ratio groups. A multivariate analysis indicated that the ratio of proliferating CD8 to CD4 was an independent prognostic factor for OS.
Conclusions
A high CD8/CD4 ratio among proliferating T cells in circulation could be associated with a better prognosis in patients with AGC receiving first-line chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract